Hillstream BioPharma Overview
Valuation check: HILS's ROE is -21.57%, below the sector sector average of -5.72%.
Get informed when a big investor buys or sells
+ Follow-21.57%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for HILS is -21.57%. That is below the sector sector average of -5.72%. Investors often review this figure alongside Hillstream BioPharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, HILS currently prints -21.57% for ROE, while the sector average sits near -5.72%. That is roughly 276.9% below the sector mean. Large gaps often invite a closer look at Hillstream BioPharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Hillstream BioPharma converts resources into returns. At -21.57%, HILS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting HILS's ROE (-21.57%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
